TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00865189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Radiotherapy
Description: Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
Study: NCT01739907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women
Study: NCT03379051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: PI3K-Delta Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: PI3K-Delta Inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Glycoengineered Anti-CD20 mAb

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Glycoengineered Anti-CD20 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
Study: NCT00865189

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Radiotherapy
Description: Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical rectal excision based on the TME technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical rectal excision based on the TME technique.
Study: NCT01529918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CANRISK (Canadian Diabetes Association Assessment)
Description: Self-risk assessment questionnaire for diabetes
Study: NCT00436904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg Monday, Wednesday, and Friday x 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
Study: NCT01173471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: tablet, oral, one tablet once daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet, oral, one tablet once daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: tablet, oral 2 tablets twice daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets, oral, 2 tablets twice daily, 28 days
Study: NCT02908737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bass and Treble
Description: Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
Study: NCT03008486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real soft splint (6 cm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real soft splint (6 cm)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft splint (1 cm)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft splint (1 cm)
Study: NCT03028740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
Study: NCT01973816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;
Description: Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rectal shaving; rectal disc excision; colorectal resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg; estradiol 0.5% percutaneous
Description: Daily intake for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
Description: Daily intake during 24 months
Study: NCT02710851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dosage HPV Vaccine(1:1)
Description: Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.
Study: NCT02674165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HART
Description: Skills based sexual education intervention plus PTSD awareness
Study: NCT01229891

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plain yogurt drink
Description: daily intake of two bottle of plain yogurt drink
Study: NCT03516214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
Study: NCT02606214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Study: NCT01229891

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D fortified yogurt drink
Description: daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D-calcium yogurt drink
Description: daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
Study: NCT01544686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV
Description: Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV
Description: Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
Study: NCT02710851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dosage HPV Vaccine(1:2)
Description: Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage HPV Vaccine(1:1)
Description: Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis E vaccine,Hecolin®
Description: Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
Study: NCT00940524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, Mitoxantrone, Cytarabine
Description: INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29
Study: NCT01062087

Intervention type: DRUG
Intervention: Bupivacaine, Lidocaine
Description: Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
Study: NCT02013128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (IV infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib oral daily dose
Study: NCT03051828

Intervention type: PROCEDURE
Intervention: fencing
Description: No intervention: practice fencing
Study: NCT03728504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily dose of Placebo Oral Tablet for 16 weeks
Study: NCT04675606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fiber diet
Description: Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
Study: NCT00282568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Modified Release (MR)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study: NCT04268095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing protocol
Description: Patients are assigned with different postoperative dressing protocols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing protocol
Description: Patients are assigned with different postoperative dressing protocols.
Study: NCT00963404

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation boost
Description: Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
Study: NCT01266122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
Study: NCT03756571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthoses-Footwear Combination
Description: This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
Study: NCT04268095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing protocol
Description: Patients are assigned with different postoperative dressing protocols.
Study: NCT02671461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02261883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Remodulin
Description: Treprostinil is a chemically stable tricyclic analogue of prostacyclin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
Study: NCT04169854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Description: The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Study: NCT02881879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot DPT/DF (50:50)
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
Study: NCT02229110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal
Description: Automatic signal in the electronic medical record
Study: NCT01412060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
Study: NCT02963415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
Study: NCT00168064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechlorethamine-MCH (nitrogen mustard)
Description: All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechlorethamine-MCH (nitrogen mustard)
Description: All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
Study: NCT05267197

Intervention type: OTHER
Intervention: 3D Telemedicine
Description: 3D Telemedicine system

Intervention type: OTHER
Intervention: 2D Telemedicine
Description: 2D Telemedicine system
Study: NCT01159509

Intervention type: BEHAVIORAL
Intervention: sodium taste tests
Description: The cohort group will had sodium taste tests and an interview regarding diat habits.
Study: NCT00423241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEMPERFLO Pain Management System
Description: continuous infusion of 0.5% bupivacaine at 2mL per hour

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ON-Q PainBuster Post-Op Pain Relief System
Description: continuous infusion of 0.5% bupivacaine at 2mL per hour
Study: NCT01179347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® inhaler
Description: to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat® inhaler
Description: patient to receive placebo matching active drug once daily
Study: NCT02986919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0610
Description: * Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area.
Study: NCT03756571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Solid Ankle AFO (TSAFO)
Description: This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
Study: NCT01902784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Interview
Study: NCT03480958

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravenous morphine patient controlled device
Description: 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled device
Description: 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled device
Description: 24 hour morphine consumption will be recorded

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: erector spinae plane block will be administered before the surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: thoracic paravertebral block will be administered before the surgery
Study: NCT03752333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.
Study: NCT02272283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation
Description: The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation
Description: The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
Study: NCT00051129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 15 mg sterile suspension
Description: 0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered as a posterior juxtascleral injection
Study: NCT01566201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anakinra
Description: Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: water for injection
Study: NCT00691093

Intervention type: DRUG
Intervention: fesoterodine
Description: 4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
Study: NCT02850744

Intervention type: DRUG
Group type: OTHER
Intervention: PQR309
Description: 80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
Study: NCT02118064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT-Irinotecan
Description: 500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
Study: NCT00529516

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Influenza Vaccine GSK576389A
Description: Single dose, Intramuscular injection
Study: NCT02060955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab/Irinotecan
Description: Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
Study: NCT01331720

Intervention type: DRUG
Intervention: hMG-HP

Intervention type: DRUG
Intervention: hMG-HP

Intervention type: DRUG
Intervention: hMG-HP

Intervention type: DRUG
Intervention: hMG-HP

Intervention type: DRUG
Intervention: hMG-HP
Study: NCT02241928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal Autologous bone marrow mononuclear cell transplantation
Study: NCT00684112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.